Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | GBA1 | P04062 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.31 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.31 |
| ▸ | GANAB | Q14697 | 1/20 | 0.31 |
| ▸ | GLB1 | P16278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1865298 | 0.82 | — | — | |
| SCHEMBL1856934 | 0.78 | GBA1 (0.33) | GAAGBA1MEN1CYP1A2CYP2C9 | |
| SCHEMBL19554428 | 0.78 | — | — | |
| SCHEMBL587533 | 0.76 | GAA (0.35) | GAAGBA1MEN1CYP1A2CYP2C9 | |
| SCHEMBL586660 | 0.76 | GAA (0.31) | GAAGBA1MEN1CYP1A2CYP2C9 | |
| SCHEMBL23475172 | 0.76 | SMN1; SMN2 (0.42) | GBA1GLB1 | |
| SCHEMBL14120089 | 0.76 | SMN1; SMN2 (0.42) | GBA1GLB1 | |
| SCHEMBL13037926 | 0.76 | SMN1; SMN2 (0.42) | GBA1GLB1 | |
| Hydrochloric Acid SCHEMBL588645 | 0.74 | GAA (0.30) | GAAGBA1MEN1CYP1A2CYP2C9 | |
| SCHEMBL22047558 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049678-A2 | TREATMENT OF ENERGY UTILIZATION DISEASES | SUMMIT CORPORATION PLC (GB) | 2010-05-06 | — | — | WO | disclosed |